Stock News

How Analysts Rated Tesaro, Inc. (NASDAQ:TSRO) Last Week?

Tesaro, Inc. (NASDAQ:TSRO) LogoInvestors sentiment decreased to 0.93 in 2018 Q2. Its down 0.21, from 1.14 in 2018Q1. It fall, as 59 investors sold Tesaro, Inc. shares while 44 reduced holdings. 29 funds opened positions while 67 raised stakes. 58.58 million shares or 3.28% less from 60.57 million shares in 2018Q1 were reported.
Amalgamated Natl Bank reported 9,011 shares or 0.01% of all its holdings. Acuta Capital Prtnrs Limited Com invested in 50,000 shares or 0.4% of the stock. Susquehanna Gp Limited Liability Partnership accumulated 268,250 shares. California Pub Employees Retirement Sys accumulated 0% or 58,200 shares. First Mercantile Trust reported 8,108 shares. Moreover, Hsbc Public Limited Co has 0% invested in Tesaro, Inc. (NASDAQ:TSRO). Metropolitan Life Insurance New York has invested 0% in Tesaro, Inc. (NASDAQ:TSRO). Moreover, Elk Creek Ltd Liability Com has 0.47% invested in Tesaro, Inc. (NASDAQ:TSRO). 8,245 were reported by Public Employees Retirement Association Of Colorado. Invesco Limited invested in 91,665 shares or 0% of the stock. Prelude Cap Management Ltd Llc reported 8,842 shares. Tiaa Cref Mngmt Ltd Com accumulated 1.07M shares. Moreover, Massachusetts Financial Services Ma has 0% invested in Tesaro, Inc. (NASDAQ:TSRO) for 77,132 shares. 75,000 are owned by State Common Retirement Fund. Group One Trading Limited Partnership has invested 0.02% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO).

Since June 12, 2018, it had 0 insider buys, and 2 sales for $310,256 activity. $2,336 worth of stock was sold by Oliveira Orlando on Saturday, September 1.

Tesaro, Inc. (NASDAQ:TSRO) Ratings Coverage

Among 5 analysts covering Tesaro (NASDAQ:TSRO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Tesaro had 10 analyst reports since May 31, 2018 according to SRatingsIntel. Citigroup maintained it with “Buy” rating and $85 target in Wednesday, August 29 report. The firm has “Overweight” rating given on Monday, October 22 by Cantor Fitzgerald. Barclays Capital upgraded Tesaro, Inc. (NASDAQ:TSRO) on Wednesday, June 27 to “Buy” rating. The stock of Tesaro, Inc. (NASDAQ:TSRO) has “Buy” rating given on Thursday, May 31 by Citigroup. The stock of Tesaro, Inc. (NASDAQ:TSRO) has “Overweight” rating given on Monday, August 6 by Barclays Capital. The stock has “Neutral” rating by Bank of America on Friday, November 2. The firm has “Neutral” rating by Bank of America given on Tuesday, September 11. On Monday, August 6 the stock rating was downgraded by Bank of America to “Neutral”. Below is a list of Tesaro, Inc. (NASDAQ:TSRO) latest ratings and price target changes.

02/11/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $38 New Target: $39 Maintain
22/10/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $57 New Target: $68 Maintain
01/10/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $57 Initiates Coverage On
25/09/2018 Broker: Leerink Swann Rating: Outperform New Target: $48 Initiates Coverage On
11/09/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $35 New Target: $38 Maintain
29/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $100 New Target: $85 Maintain
06/08/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $60 New Target: $56 Maintain
06/08/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade
27/06/2018 Broker: Barclays Capital Rating: Buy New Target: $60.0000 Upgrade
31/05/2018 Broker: Citigroup Rating: Buy New Target: $100.0000 Maintain

The stock decreased 18.80% or $5.81 during the last trading session, reaching $25.1. About 3.88 million shares traded or 125.64% up from the average. Tesaro, Inc. (NASDAQ:TSRO) has declined 70.32% since November 10, 2017 and is downtrending. It has underperformed by 85.94% the S&P500.

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. The company has market cap of $1.38 billion. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. It currently has negative earnings. The firm is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers.

More notable recent Tesaro, Inc. (NASDAQ:TSRO) news were published by: Globenewswire.com which released: “TESARO Announces Data Presentations at ESMO 2018 Congress” on October 20, 2018, also Seekingalpha.com with their article: “Tesaro down 19% on disappointing early-stage data on cancer combo” published on November 09, 2018, Nasdaq.com published: “Here’s Why AnaptysBio, Inc. Slipped on Friday” on November 09, 2018. More interesting news about Tesaro, Inc. (NASDAQ:TSRO) were released by: Seekingalpha.com and their article: “Tesaro Q3 Zejula sales up 60%; shares up 4% after hours” published on November 01, 2018 as well as Globenewswire.com‘s news article titled: “TESARO Announces Third-Quarter 2018 Operating Results” with publication date: November 01, 2018.

Tesaro, Inc. (NASDAQ:TSRO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*